AzarGen And iBio Push On With Plant-Based Rituximab

Biosimilar Development Aimed Towards African Continent

 
• By Dean Rudge

AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.

Plants_Biochemistry
AzarGen and iBio signed a master joint development agreement two years ago • Source: Shutterstock

More from Biosimilars

More from Products